225377-55-9

Basic information

• Product Name: 3-<(R)-<2-(1,1-dimethylethoxy)-2-oxoethyl>-1-oxopentyl>-4(S)-(phenylmethyl)-2-oxazolidinone
• Synonyms: 3-<(R)-<2-(1,1-dimethylethoxy)-2-oxoethyl>-1-oxopentyl>-4(S)-(phenylmethyl)-2-oxazolidinone
• CAS NO: 225377-55-9
• Molecular Weight: 375.465
• Mol File: 225377-55-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-<(R)-<2-(1,1-dimethylethoxy)-2-oxoethyl>-1-oxopentyl>-4(S)-(phenylmethyl)-2-oxazolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-<(R)-<2-(1,1-dimethylethoxy)-2-oxoethyl>-1-oxopentyl>-4(S)-(phenylmethyl)-2-oxazolidinone(225377-55-9)
• EPA Substance Registry System: 3-<(R)-<2-(1,1-dimethylethoxy)-2-oxoethyl>-1-oxopentyl>-4(S)-(phenylmethyl)-2-oxazolidinone(225377-55-9)

Safety Data

• Hazardous Substances Data: 225377-55-9(Hazardous Substances Data)

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 109-52-4 valeric acid 
• 638-29-9 n-valeryl chloride 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 
• 143868-89-7 3-(1-oxopentyl)-4(S)-(phenylmethyl)-2-oxazolidinone 

Downstream Products

• 112106-15-7 (2R)-2-propyl-succinic acid 1-benzyl ester 4-tert-butyl ester 
• 63095-51-2 (+)-(R)-4-propyl-4,5-dihydrofuran-2(3H)-one 
• 357336-20-0 brivaracetam 
• 225377-74-2 N-<1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl>-2(R)-<2-(1,1-dimethylethoxy)-2-oxoethyl>pentanamide 
• 225378-26-7 (R)-3-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-hexanoic acid 
• 847910-42-3 1-(2(R)-tert-butoxycarbonylmethylpentanoyl)proline benzyl ester 
• 847910-50-3 1-(2(R)-carbonylmethylpentanoyl)proline benzyl ester 

Relevant articles and documents

Preparation method of (R)-4-propyl-dihydrofuran-2-one and preparation intermediate of (R)-4-propyl-dihydrofuran-2-one

The invention discloses a preparation method of (R)-4-propyl-dihydrofuran-2-one and a preparation intermediate of (R)-4-propyl-dihydrofuran-2-one. The preparation method of the intermediate comprisesthe following steps: (1) in the presence of an acid or an alkali, carrying out hydrolysis reaction on a compound I to obtain a compound II or a salt thereof; and (2) carrying out reduction reaction onthe compound II or the salt thereof and a reducing agent to obtain a compound III. According to the preparation route disclosed by the invention, the use of flammable and explosive reaction reagentsin the existing route is avoided; reagents which are low in cost and easy to obtain in industry are used; compared with the prior art, the method has the advantages of low cost, safety in production,realization of the purification and the separation of the intermediate by using the acid-base property of the compound and adopting the mode of adjusting the pH value of the system in the reaction process and the post-treatment operation, avoiding of recrystallization, filtration and other tedious operation modes, simplification of the operation, and suitableness for industrial large-scale production.

New synthesis method of brivaracetam

The invention provides a synthesis method of brivaracetam. The method adopts cheap and easily available pentanoic acid or valeryl halide as an initial raw material, and provides a brand new synthesis route of a brivaracetam medicine, and the whole reaction route has a high total yield. The method has the advantages of high productivity, low cost, and suitableness for large-scale industrial production.

Treatment of diseases using ICE inhibitors

This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases.